Somatostatin Receptor Imaging in NPC, EBV Related Cancers

National Cancer Centre, Singapore

Status: Enrolling

Conditions: Nasopharyngeal Cancer; Epstein-Barr Virus Related Carcinoma

Treatments: Radiation: Galium-68 DOTATATE; Radiation: FDG-PET

Study type: Interventional

Funder types: Other

Identifiers

NCT05581550

NPC EBV SSTR

Details and patient eligibility

About

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Enrollment: 50 estimated patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
• Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
• Histologically confirmed NPC
• Above 21 years of age

Exclusion criteria

• Patients below 21 years of age
• Pregnant and breast feeding ladies

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

PET imaging

Other group

Treatment:

Radiation: Galium-68 DOTATATE

Radiation: FDG-PET